COST EFFECTIVENESS ANALYSIS OF ANTIBIOTICS USE OF PNEUMONIA PATIENS WITH HOSPITALIZATION IN RSU MUHAMMADIYAH SITI AMINAH BUMIAYU IN 2021

Abstract

Pneumonia is an infectious disease that is the highest cause of death in children and the elderly. Cost  is one of the most important factor to consider in health care. The purpose of this study was to  analyze the cost-effectiveness of using antibiotics in patients with pneumonia in RSU Muhammadiyah Siti  Aminah Bumiayu. This study uses a descriptive method with retrospective data collection. The sample was obtained by purposive sampling method in patients with a diagnosis of pneumonia who were hospitalized in 2021, were general patients who received antibiotic therapy with complete medical record data and financing data, therefore a study sample of 28 patients was obtained. The results of this study showed that there were eight antibiotic therapy profiles in pneumonia patients, namely Ampisilin Sulbaktam (25,0%), Levofloxacin+ Ceftriaxone (17,9%), Levofloxacin (14,3%), Cefotaxime (14,3%), Azitromisin+ Ceftazidim (10,7), Ampisilin Sulbaktam+ Cefotaxime (7,1%), Azitromisin + Levofloxacin (7,1%) and Ceftriaxone (3,6%).  The result of calculating the ACER value is known that the most cost-effective antibiotic is Cefotaxime with an ACER value of Rp. 2.701.625,-

Keywords: Pneumonia, Antibiotics, Cost-effectiveness, ACER, ICER